COMP <GO>
ALNY vs MRK // REVENUE GROWTH (YOY)
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ALNY 5
— MRK 10
▲ REVENUE GROWTH (YOY) LEADER: ALNY
LAST: $165.00 (-5.17%) • MKT CAP: $23.28B
revenue-growth
65.20%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 74.80% | +7.00 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 20.70% | +0.60 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 15.3x | +27.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 3.42% | -1.42 | MRK | /fcf-yield <GO> |
| Operating Margin | 13.50% | 34.30% | -20.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 28.10% | -19.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 65.20% | 1.30% | +63.90 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 5.19 | -2.03 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.1 | 56.9 | -34.81 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | ALNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 18.4x | +43.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.28B | $361.02B | -$337.74B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | MRK REV | ALNY GROSS % | MRK GROSS % | ALNY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $65.01B | 81.8% | 74.8% | $465.4M | $12.36B |
| FY 2024 | $2.25B | $64.17B | 86.4% | 76.3% | -$42.6M | $18.10B |
| FY 2023 | $1.83B | $60.12B | 44.0% | 44.0% | $21.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
MRK // BETA 0.92